vs

Side-by-side financial comparison of enCore Energy Corp. (EU) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $12.4M, roughly 1.7× enCore Energy Corp.). Pulmonx Corp runs the higher net margin — -66.3% vs -173.9%, a 107.6% gap on every dollar of revenue.

Devon Energy Corporation is an American company engaged in hydrocarbon exploration. It is organized in Delaware with operational headquarters in the 50-story Devon Energy Center in Oklahoma City, Oklahoma. Its operations are in the Delaware Basin, Eagle Ford Group, and the Rocky Mountains.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

EU vs LUNG — Head-to-Head

Bigger by revenue
LUNG
LUNG
1.7× larger
LUNG
$20.6M
$12.4M
EU
Higher net margin
LUNG
LUNG
107.6% more per $
LUNG
-66.3%
-173.9%
EU

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
EU
EU
LUNG
LUNG
Revenue
$12.4M
$20.6M
Net Profit
$-21.5M
$-13.7M
Gross Margin
37.9%
77.9%
Operating Margin
-135.9%
-40.9%
Net Margin
-173.9%
-66.3%
Revenue YoY
-8.7%
Net Profit YoY
5.5%
EPS (diluted)
$-0.11
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EU
EU
LUNG
LUNG
Q1 26
$20.6M
Q4 25
$12.4M
$22.6M
Q3 25
$8.9M
$21.5M
Q2 25
$3.7M
$23.9M
Q1 25
$18.2M
$22.5M
Q4 24
$23.8M
Q3 24
$20.4M
Q2 24
$20.8M
Net Profit
EU
EU
LUNG
LUNG
Q1 26
$-13.7M
Q4 25
$-21.5M
$-10.4M
Q3 25
$-4.8M
$-14.0M
Q2 25
$-6.3M
$-15.2M
Q1 25
$-24.2M
$-14.4M
Q4 24
$-13.2M
Q3 24
$-14.1M
Q2 24
$-15.3M
Gross Margin
EU
EU
LUNG
LUNG
Q1 26
77.9%
Q4 25
37.9%
77.6%
Q3 25
43.8%
74.7%
Q2 25
30.8%
72.1%
Q1 25
-0.1%
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
EU
EU
LUNG
LUNG
Q1 26
-40.9%
Q4 25
-135.9%
-43.8%
Q3 25
-158.2%
-66.9%
Q2 25
-526.1%
-62.0%
Q1 25
-85.7%
-64.6%
Q4 24
-56.5%
Q3 24
-69.3%
Q2 24
-75.2%
Net Margin
EU
EU
LUNG
LUNG
Q1 26
-66.3%
Q4 25
-173.9%
-46.1%
Q3 25
-53.7%
-64.9%
Q2 25
-172.7%
-63.6%
Q1 25
-132.9%
-64.1%
Q4 24
-55.4%
Q3 24
-69.4%
Q2 24
-73.7%
EPS (diluted)
EU
EU
LUNG
LUNG
Q1 26
$-0.33
Q4 25
$-0.11
$-0.25
Q3 25
$-0.03
$-0.34
Q2 25
$-0.03
$-0.38
Q1 25
$-0.13
$-0.36
Q4 24
$-0.33
Q3 24
$-0.36
Q2 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EU
EU
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$52.4M
$61.6M
Total DebtLower is stronger
$110.0M
$37.3M
Stockholders' EquityBook value
$229.2M
$45.8M
Total Assets
$430.4M
$120.0M
Debt / EquityLower = less leverage
0.48×
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EU
EU
LUNG
LUNG
Q1 26
$61.6M
Q4 25
$52.4M
$69.8M
Q3 25
$91.9M
$76.5M
Q2 25
$26.9M
$75.5M
Q1 25
$29.7M
$74.6M
Q4 24
$70.9M
Q3 24
$63.3M
Q2 24
$63.5M
Total Debt
EU
EU
LUNG
LUNG
Q1 26
$37.3M
Q4 25
$110.0M
$37.1M
Q3 25
$109.3M
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
EU
EU
LUNG
LUNG
Q1 26
$45.8M
Q4 25
$229.2M
$54.1M
Q3 25
$248.6M
$60.0M
Q2 25
$264.7M
$69.1M
Q1 25
$267.9M
$77.7M
Q4 24
$85.8M
Q3 24
$93.9M
Q2 24
$101.2M
Total Assets
EU
EU
LUNG
LUNG
Q1 26
$120.0M
Q4 25
$430.4M
$129.3M
Q3 25
$441.9M
$138.3M
Q2 25
$359.4M
$147.2M
Q1 25
$362.6M
$150.7M
Q4 24
$162.8M
Q3 24
$167.4M
Q2 24
$172.6M
Debt / Equity
EU
EU
LUNG
LUNG
Q1 26
0.82×
Q4 25
0.48×
0.69×
Q3 25
0.44×
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EU
EU
LUNG
LUNG
Operating Cash FlowLast quarter
$12.9M
Free Cash FlowOCF − Capex
$7.2M
FCF MarginFCF / Revenue
57.8%
Capex IntensityCapex / Revenue
46.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-45.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EU
EU
LUNG
LUNG
Q1 26
Q4 25
$12.9M
$-7.1M
Q3 25
$-20.3M
$-8.2M
Q2 25
$-9.9M
$-3.9M
Q1 25
$-7.7M
$-13.2M
Q4 24
$-6.7M
Q3 24
$-7.2M
Q2 24
$-5.8M
Free Cash Flow
EU
EU
LUNG
LUNG
Q1 26
Q4 25
$7.2M
$-7.1M
Q3 25
$-26.3M
$-8.3M
Q2 25
$-14.1M
$-4.0M
Q1 25
$-11.7M
$-13.5M
Q4 24
$-6.8M
Q3 24
$-7.7M
Q2 24
$-6.2M
FCF Margin
EU
EU
LUNG
LUNG
Q1 26
Q4 25
57.8%
-31.4%
Q3 25
-296.6%
-38.4%
Q2 25
-385.2%
-16.6%
Q1 25
-64.1%
-60.0%
Q4 24
-28.8%
Q3 24
-37.6%
Q2 24
-30.0%
Capex Intensity
EU
EU
LUNG
LUNG
Q1 26
Q4 25
46.7%
0.1%
Q3 25
68.0%
0.4%
Q2 25
115.1%
0.2%
Q1 25
21.7%
1.3%
Q4 24
0.5%
Q3 24
2.0%
Q2 24
2.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons